An open-label study to evaluate the trough and peak effect of once daily Micardis Plus (telmisartan 80mg / hydrochlorothiazide 12.5 mg) by 24 ABPM [ambulatory blood pressure monitoring] in patients with mild to moderate essential hypertension

Trial Profile

An open-label study to evaluate the trough and peak effect of once daily Micardis Plus (telmisartan 80mg / hydrochlorothiazide 12.5 mg) by 24 ABPM [ambulatory blood pressure monitoring] in patients with mild to moderate essential hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Telmisartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 29 Sep 2009 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
    • 30 Aug 2007 Status changed from recruiting to completed.
    • 15 Sep 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top